Document is current
Any future updates will be listed below
-
Authors
Ryder, Mark I. http://orcid.org/0000-0002-8540-4017
- License Information
-
More Information
Article History
Accepted: 12 September 2022
First Online: 23 September 2022
Declarations
:
: The multi-center GAIN Trial protocol and the COR 588 Phase 1 Trial protocol described with results in this review were approved by an institutional review board at each site and were conducted in accordance with Good Clinical Practice guidelines. All of the participants or their legal representatives provided written informed consent. The sponsor (Cortexyme) designed and funded the trial, supplied treatment and placebo, and oversaw the contracted research organization.
: Mark I. Ryder, the author of this review, previously served as a member of the Clinical Advisory Board, holds stock, and receives consultant fees from Cortexyme Inc./Quince Therapeutics.
